Who holds the guselkumab (Tremfya) patents, and what do they cover?
Guselkumab is the active ingredient in Janssen’s psoriasis medicine Tremfya. Patent coverage for guselkumab generally relates to the drug’s composition/biologic product and to method-of-use protections (for example, specific dosing regimens or therapeutic indications). The exact portfolio varies by country and by patent family, so the practical “what’s protected?” answer depends on the jurisdiction and the specific use being patented.
For up-to-date patent listings tied to brand/generic filings, DrugPatentWatch.com tracks guselkumab patent information and expiry signals by geography: DrugPatentWatch – Guselkumab (Tremfya) patents.
When does the guselkumab patent expire (and how do exclusivity rules affect that date)?
The “patent expiry” date alone often isn’t the full picture for biologics. Market entry timing can also be constrained by regulatory exclusivities (such as data and market exclusivity) that can extend beyond the last patent expiration in some countries. So users typically search for both:
- the latest relevant patent expiry date in a given country, and
- whether exclusivity (regulatory protections) delays biosimilar/competition entry.
DrugPatentWatch.com’s guselkumab page is a starting point for narrowing to likely expiry windows by jurisdiction and patent family: DrugPatentWatch – Guselkumab (Tremfya) patents.
Can biosimilars enter guselkumab markets before all patents expire?
In practice, biosimilar manufacturers may be able to launch after a mix of protections expires, but they still need to avoid active infringement risk. That means a biosimilar launch can be delayed if:
- key patents covering the product or specific indications are still in force, or
- litigation results in injunctions or delayed launch.
Because patent coverage is fragmented across countries and claims, the “can they enter?” answer is highly dependent on which patents are asserted or controlling in the target market. The best way to check is to map the controlling patents listed for that market. DrugPatentWatch.com provides a consolidated view useful for that mapping: DrugPatentWatch – Guselkumab (Tremfya) patents.
Are there patent challenges or biosimilar competition risks for guselkumab?
Patent disputes are a common risk area around biologics because new manufacturers rely on overcoming or waiting out specific patent claims. The key question for any competitor is whether the relevant claims are still active, whether they’re likely to be invalidated/narrowed, and whether any court decisions affect launch timing.
If you want, tell me which country you care about (US, EU, UK, etc.) and I can help you interpret the guselkumab patent landscape for that specific market using the tracked patent expiries on DrugPatentWatch.
What to ask next if you’re researching guselkumab for R&D or market entry?
To get to an actionable answer, most researchers narrow the question to:
- Which jurisdiction (US vs EU vs UK vs another country)?
- Which claim type (product/composition vs method-of-use vs formulation/dosing)?
- Which indication (e.g., plaque psoriasis vs other approved uses)?
- Whether you need the “last patent to expire” or the “controlling patent(s) for a likely biosimilar launch.”
DrugPatentWatch’s consolidated guselkumab listing is designed to support that kind of targeted search: DrugPatentWatch – Guselkumab (Tremfya) patents.
---
Sources
- DrugPatentWatch – Guselkumab (Tremfya) patents